Newer insights into the drug delivery approaches of α-glucosidase inhibitors

Bibliography

• IDF. International diabetes federation. Diabetes Atlas. 4th edition. 2009
   Google Scholar
• Davis SN, Granner DK. Insulin, oral hypoglycemic agents, and the pharmacology of the endocrine pancreas. Goodman & Gilman's Pharmacological Basis of Therapeutics. 11th edition. McGraw-Hill Medical Publishing Division; New York: 2006. p. 1635
   Google Scholar
• Ceriello A. Postprandial hyperglycemia and diabetes complications. Diabetes 2005;54(1):1
   PubMed Web of Science ®Google Scholar
• Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003;163(11):1306
   PubMed Web of Science ®Google Scholar
• Gavin JR. Pathophysiologic mechanisms of postprandial hyperglycemia. Am J Cardiol 2001;88(6):4-8
   Google Scholar
• Ratner RE. Controlling postprandial hyperglycemia. Am J Cardiol 2001;88(6):26-31
   Google Scholar
• de Veciana M, Major CA, Morgan MA, Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333(19):1237
   PubMed Web of Science ®Google Scholar
• Turner RC, Cull CA, Frighi V, Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999;281(21):2005
   PubMed Web of Science ®Google Scholar
• Nolte MS, Karam JH. Pancreatic hormones and antidiabetic drugs. Basic and Clinical Pharmacology. 10th edition. Mc-Graw Hill, New York, NY; 2007. p. 697-8
   Google Scholar
• Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997;26(3):539
   PubMed Web of Science ®Google Scholar
• Scheen J, Lefebvre PJ. Oral antidiabetic agents: a guide to selection. Drugs 1998;55(2):225-36
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus? Drugs 2003;63(10):933-51
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Hunt JA, The efficacy of acarbose in the treatment of patients with non–insulin-dependent diabetes mellitus: a multicenter, controlled clinical trial. Ann Intern Med 1994;121(12):928
   PubMed Web of Science ®Google Scholar
• Johnston PS, Feig PU, Coniff RF, Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998;21(3):416
   PubMed Web of Science ®Google Scholar
• Welborn TA, Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care 1979;2(2):154
   PubMedGoogle Scholar
• Despres JP, Lamarche B, Mauriege P, Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334(15):952
   PubMed Web of Science ®Google Scholar
• van de Laar FA, Lucassen PL. Akkermans RP, et al. -Glucosidase inhibitors for patients with type 2 diabetes. Diabetes Care 2005;28(1):154
   PubMed Web of Science ®Google Scholar
• Frommer W, Junge B, Keup U, Amino sugar derivatives. Assigned to Bayer Aktiengesellschaft (DT). US4062950; 1977
   Google Scholar
• Williams DA, Foye WO, Lemke TL. Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins, US; 2002
   Google Scholar
• Muller L, Puls W. Pharmacology of alpha-glucosidase inhibitors. Structure and function of the small intestine Amsterdam. Excepta Med 1988;281-300
   Google Scholar
• Ziese T, Kruger D, Grossklaus R. In vitro and in vivo inhibition of small intestinal digestion of sugar substitutes by acarbose. Aktuelle Ernahrungsmedizin 1995;20(4):229-31
   Google Scholar
• Clissold SP, Edwards C. Acarbose. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1988;35(3):214
   PubMed Web of Science ®Google Scholar
• Putter J, Keup U, Krause H, Pharmacokinetics of acarbose. Excerpta Med 1982;38
   Google Scholar
• Ruppin H, Hagel J, Feuerbach W, Fate and effects of the alpha-glucosidase inhibitor acarbose in humans. An intestinal slow-marker perfusion study. Gastroenterology 1988;95(1):93
   PubMed Web of Science ®Google Scholar
• Salehi A, Panagiotidis G, Borg LA, The pseudotetrasaccharide acarbose inhibits pancreatic islet glucan-1, 4-alpha-glucosidase activity in parallel with a suppressive action on glucose-induced insulin release. Diabetes 1995;44(7):830
   PubMed Web of Science ®Google Scholar
• Chiasson JL, Josse RG, Gomis R, Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002;359(9323):2072-7
   PubMed Web of Science ®Google Scholar
• Krause HP, Keup U, Thomas G, Reduction of carbohydrate-induced hypertriglyceridemia in (fa, fa)'Zucker'rats by the a-glucosidase inhibitor acarbose (BAY g 5421). Metabolism 1982;31:710-14
   PubMed Web of Science ®Google Scholar
• Rosak C, Nitzsche G, Konig P, The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995;12(11):979-84
   PubMed Web of Science ®Google Scholar
• Hillebrand I, Boehme K, Graefe KH, The effect of new alpha-glucosidase inhibitors (Baym1099 and Bayo1248) on meal-stimulated increases in glucose and insulin levels in man. KIinische Wochenschrifi 1986;64:393-6
   PubMed Web of Science ®Google Scholar
• Scheppach W, Fabian C, Ahrens F, Effect of starch malabsorption on colonic function and metabolism in humans. Gastroenterology 1988;95(6):1549
   PubMed Web of Science ®Google Scholar
• Pinol C, Guardiola E, Soler J, A double blind, randomised, placebo controlled study to assess the maximum insulin dose reduction achieved with acarbose in the treatment of insulin-requiring type 2 diabetic patients. Diabetes Nutr Metab 1998;11(4):242-8
   Google Scholar
• Cohen-Melamed E, Nyska A, Pollack A, Aldose reductase (EC 1.1. 1.21) activity and reduced-glutathione content in lenses of diabetic sand rats (Psammomys obesus) fed with acarbose. Br J Nutr 1995;74(05):607-15
   PubMedGoogle Scholar
• Takagi C, King GL, Clermont AC, Reversal of abnormal retinal hemodynamics in diabetic rats by acarbose, an -glucosidase inhibitor. Curr Eye Res 1995;14(9):741-9
   PubMed Web of Science ®Google Scholar
• Junge B, Krause HP, Muller L, Antidiabetic 3, 4, 5-trihydroxypiperidines. Assigned to Bayer Aktiengesellschaft. US4639436; 1987
   Google Scholar
• Scott LJ, Spencer CM. Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. Drugs 2000;59(3):521-49
   PubMed Web of Science ®Google Scholar
• Schall R, Muller FO, Hundt HK, Study of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males. Arzneimittel-Forschung 1996;46(1):41
   PubMed Web of Science ®Google Scholar
• Kingma PJ, Menheere PP, Sels JP, Alpha-Glucosidase inhibition by miglitol in NIDDM patients. Diabetes Care 1992;15(4):478
   PubMed Web of Science ®Google Scholar
• Ladas SD, Frydas A, Papadopoulos A, Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans. Gut 1992;33(9):1246
   PubMed Web of Science ®Google Scholar
• Pagano G, Marena S, Corgiat-Mansin L, Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. Diab Metab 1995;21(3):162-7
   PubMed Web of Science ®Google Scholar
• Aoki K, Muraoka T, Ito Y, Comparison of adverse gastrointestinal effects of acarbose and miglitol in healthy men: a crossover study. Intern Med 2010;49(12):1085-7
   PubMed Web of Science ®Google Scholar
• Aoki K, Miyazaki T, Nagakura J, Effects of pre-meal versus post-meal administration of miglitol on plasma glucagon-like peptide-1 and glucosedependent insulinotropic polypeptide levels in healthy men. Endocr J 2010;57(8):673
   PubMed Web of Science ®Google Scholar
• Aoki K, Kato H, Terauchi Y. Divided-dose administration of miglitol just before and 15 minutes after the start of a meal smoothes postprandial plasma glucose excursions and serum insulin responses in healthy men. Endocr J 2007;54(6):1009-14
   PubMed Web of Science ®Google Scholar
• Masuda K, Aoki K, Terauchi Y. Effects of miglitol taken just before or after breakfast on plasma glucose, serum insulin, glucagon and incretin levels after lunch in men with normal glucose tolerance, impaired fasting glucose or impaired glucose tolerance. J Diabetes Investig 2011;2(6):435-40
   PubMedGoogle Scholar
• Aoki K, Nakajima S, Nezu U, Comparison of pre-vs. postmeal administration of miglitol for 3 months in type 2 diabetic patients. Diabetes Obes Metab 2008;10(10):970-2
   PubMed Web of Science ®Google Scholar
• Standl E, Schernthaner G, Rybka J, Improved glycaemic control with miglitol in inadequately-controlled type 2 diabetics. Diabetes Res Clin Pract 2001;51(3):205-13
   PubMed Web of Science ®Google Scholar
• De Luis R. Utilidad del miglitol en pacientes con diabetes mellitus tipo 2 y mal control glucemico= usefulness of miglitol in patients with diabetes mellitus type 2 and insufficient control of the blood glucose. Rev Clin Esp 2004;204(1):32-4
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Voglibose for prevention of type 2 diabetes mellitus. Lancet 2009;373(9675):1607-14
   PubMed Web of Science ®Google Scholar
• Horii S, Kameda Y, Fukase H. N-substituted pseudo-aminosugars, their production and use. Google Patents 1987
   Google Scholar
• Kawamori R, Tajima N, Iwamoto Y, Voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. Lancet 2009;373:1607-14
   PubMed Web of Science ®Google Scholar
• Shinozaki K, Suzuki M, Ikebuchi M, Improvement of insulin sensitivity and dyslipidemia with a new [alpha]-glucosidase inhibitor, voglibose, in nondiabetic hyperinsulinemic subjects* 1. Metabolism 1996;45(6):731-7
   PubMed Web of Science ®Google Scholar
• Yasuda K, Shimowada K, Uno M, Long-term therapeutic effects of voglibose, a potent intestinal alpha-glucosidase inhibitor, in spontaneous diabetic GK rats. Diabetes Res Clin Pract 2003;59(2):113-22
   PubMed Web of Science ®Google Scholar
• Hirose T, Miyashita Y, Takagi M, Characteristics of type 2 diabetic patients responding to voglibose administration as an adjunct to sulfonylurea. Diabetes Res Clin Pract 2001;54(1):9-15
   PubMed Web of Science ®Google Scholar
• Taira M, Takasu N, Komiya I, Voglibose administration before the evening meal improves nocturnal hypoglycemia in insulin-dependent diabetic patients with intensive insulin therapy. Metabolism 2000;49(4):440-3
   PubMed Web of Science ®Google Scholar
• Vichayanrat A, Ploybutr S, Tunlakit M, Efficacy and safety of voglibose in comparison with acarbose in type 2 diabetic patients. Diabetes Res Clin Pract 2002;55(2):99-104
   PubMed Web of Science ®Google Scholar
• Bae J, Jang C, Lee S. Methods for Pharmacodynamic analysis and proposed protocols for Bioequivalence Study of acarbose. Yakhak Hoeji 2007;51(6):440
   Google Scholar
• Ahr HJ, Boberg M, Brendel E, Pharmacokinetics of miglitol: absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittel-Forschung 1997;47(6):734-45
   PubMed Web of Science ®Google Scholar
• Ibrahim FA, Ali FA, Ahmed SM, Kinetic determination of acarbose and miglitol in bulk and pharmaceutical formulations using alkaline potassium permanganate. Int J Biomed Sci 2007;3:20-30; Back to cited text no. 2007;11
   PubMedGoogle Scholar
• Mallikarjuna Rao N, Bagyalakshmi J, Ravi TK. Development and validation of spectrofluorimetric method for the estimation of voglibose in bulk and pharmaceutical dosage form. J Chem Pharma Res 2010;2:350-6
   Google Scholar
• Melikian C, White TJ, Vanderplas A, Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther 2002;24(3):460-7
   PubMed Web of Science ®Google Scholar
• Ron Y, Wainstein J, Leibovitz A, The effect of acarbose on the colonic transit time of elderly long-term care patients with type 2 diabetes mellitus. J Gerontol A Biol Sci Med Sci 2002;57(2):M111
   PubMed Web of Science ®Google Scholar
• Nahoko F, Kenji N, Akitoshi N, Tablet containing acarbose. JP2009227658; 2009
   Google Scholar
• Rosner H. Use for drug acarbose for weight control prevention of weight gain for weight loss for treatment and prevention of obesity. US6387361 2002
   Google Scholar
• Morrison JU. Method and composition for controlled release acarbose formulations. Assigned to Morrison. US6849609; 2001
   Google Scholar
• Blume H, Mutschler E, Weitschies W. Peroral dosage forms to achieve a sustained-release effect after medicament dosage with a meal. US20090010906; 2005
   Google Scholar
• Devane J. Acarbose methods and formulations for treating chronic constipation. Assigned to AGI Therapeutics Research Limited. US20060229261; 2006
   Google Scholar
• Kumar VD, Prakash TNKS, Easwari TS. Formulation, characterization and in-vitro evaluation of acarbose loaded ultra-deformable liposome gel for effective transdermal delivery. Adv Pharmacol Toxicol 2010;11:43-6
   Google Scholar
• Sun G, Wu L. Acarbose Solid Sustained-Release Preparation and Preparing Method Thereof (CN200910016275). Assigned to Qingdao Huanghai Pharmaceutical Co, Ltd; 2009
   Google Scholar
• Kumar GJ V, Badoni PP, Rawat MSM, Semalty A. Formulation and release kinetic study of hydrogel containing acarbose using polymers as hydroxypropylmethyl cellulose and guar gum. J Pharm Res 2009;2:370-4
   Google Scholar
• Kumar GJ V, Badoni PP. Formulation and evaluation of matrix tablets of acarbose. Drug Invent Today 2010;2:264-7
   Google Scholar
• Kumar RV, Sinha VR. A novel synergistic galactomannan-based unit dosage form for sustained release of acarbose. AAPS PharmSciTech 2012;1-14
   PubMedGoogle Scholar
• Koh N, Sakamoto S, Chino F. Improvement in medication compliance and glycemic control with voglibose oral disintegrating tablet. Tohoku J Exp Med 2008;216(3):249-57
   PubMed Web of Science ®Google Scholar
• Shimizu T, Sugaya M, Nakano Y. Rapidly disintegrable solid preparation. Assigned to Takeda Pharmaceutical Company Ltd. US7399485; 2008
   Google Scholar
• Bechgaard H, Nielsen GH. Controlled-release multiple-units and single-unit doses a literature review. Drug Dev Ind Pharm 1978;4(1):53-67
   Web of Science ®Google Scholar
• Eskilson C. Controlled release by microencapsulation. Manufacturing Chem 1985;56(3):33-9
   Google Scholar
• Ghebre-Sellassie I. Pharmaceutical pelletization technology. 1989
   Google Scholar
• Tang ESK, Chan LW, Heng PWS. Coating of multiparticulates for sustained release. Am J Drug Deliv 2005;3(1):17-28
   Google Scholar
• Odidi A, Odidi I. Extended release pharmaceuticals. US7858119; 2001
   Google Scholar
• Deshpande MC, Venkateswarlu V, Babu RK, Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal [alpha]-glucosidases and enhancement of plasma glucagon like peptide-1 levels. Int J Pharm 2009;380(1-2):16-24
   PubMedGoogle Scholar
• Maes D, Declercq L, Corstjens H. Cosmetic compositions containing alpha glucosidase inhibitors and methods of use. WO2009038875; 2009
   Google Scholar
• Ludger MCK, Claudia M, Thomas B, Use of acarbose and its derivatives for treatment and prophylaxis of degenerative skin conditions. WO2003086420; 2003
   Google Scholar
• Rosak C, Haupt E, Walter T, The effect of combination treatment with acarbose and glibenclamide on postprandial glucose and insulin profiles: additive blood glucose lowering effect and decreased hypoglycaemia. Diabetes Nutr Metabo 2002;15(3):143-51
   PubMedGoogle Scholar
• Wagener G, Elmahdi K, Hohner U. Combination of acetylsalicylic acid and alpha-glucosidase inhibitors. US20070099850; 2004
   Google Scholar
• Aoki K, Masuda K, Miyazaki T, Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010;57(8):667
   PubMed Web of Science ®Google Scholar
• Moritoh Y, Takeuchi K, Hazama M. Combination treatment with alogliptin and voglibose increases active GLP-1 circulation, prevents the development of diabetes and preserves pancreatic beta-cells in prediabetic db/db mice. Diabetes Obes Metab 2010;12(3):224-33
   PubMed Web of Science ®Google Scholar
• Chittora NC, Shrivastava A Jain A. New RP-HPLC method of miglitol in tablet dosage form including forced degradation studies and estimation in spiked rabbit plasma. J Young Pharmacists 2010;1 (4):364-70
   Google Scholar
• Li X, Wang Y, Wang J, Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21(2):247-51
   PubMed Web of Science ®Google Scholar
• Jain R, Lukram O Dwivedi A. Ultra performance liquid chromatography electrospray ionization-tandem mass spectrometry method for the estimation of miglitol in human plasma using metformin as the internal standard. Drug Test Anal 2010; 3 (4):255-62
   PubMed Web of Science ®Google Scholar
• Nirogi RVS, Kandikere VN, Shukla M, Liquid chromatographic tandem mass spectrometry method for the quantification of miglitol in human plasma. Arzneimittelforschung. 2006;56(5):328-36
   PubMed Web of Science ®Google Scholar
• Wang F, Zhou J, Xiang D, Determination of miglitol in human plasma by HPLC-MS/ESI. Chin Pharm J 2005;40 (1).
   Google Scholar
• Woo JS Ryu JK. Quantitative determination of voglibose in pharmaceutical tablets using high-performance liquid chromatography-fluorescence detection with post-column derivatization and mass spectrometric detection. J Pharm Biomed Anal 2006;42(3):328-33
   PubMed Web of Science ®Google Scholar
• Rao NM, Kumar KR, Bagyalakshmi J, RP-HPLC method development and validation for estimation of Voglibose in bulk and tablet dosage forms. Int J Res Pharm Sci 2010;1 (2):190-4
   Google Scholar
• Xin-rong W, Min S, Bi-mei H, The application of HPLC-ELSD determination in the production of voglibose. Chin. J. Antibiot. 2009;12
   Google Scholar
• Raman NV, Reddy KR, Prasad AVSS, Development and validation of LC methods with visible detection using pre-column derivatization and mass detection for the assay of voglibose. Talanta 2009;77(5):1869-72
   PubMed Web of Science ®Google Scholar